TABLE 1.
Activities of dalbavancin and comparator agents against 81,673 gram-positive cocci isolated from 33 countries worldwide
| Organism or group and susceptibility subset (no. tested) | Antimicrobial agent | MIC (μg/ml)
|
% Susceptiblea | % Resistantb | ||
|---|---|---|---|---|---|---|
| 50% | 90% | Range | ||||
| S. aureus | ||||||
| Oxacillin susceptible (27,052) | Dalbavancin | 0.06 | 0.06 | ≤0.03-0.25 | 100.0 | — |
| Vancomycin | 1 | 1 | ≤0.12-4 | >99.9 | 0.0 | |
| Erythromycin | ≤0.25 | >2 | ≤0.25->2 | 78.7 | 20.7 | |
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25->2 | 95.8 | 4.0 | |
| Levofloxacin | ≤0.5 | ≤0.5 | ≤0.5->4 | 92.8 | 6.7 | |
| Gentamicin | ≤2 | ≤2 | ≤2->8 | 97.1 | 2.6 | |
| Tetracycline | ≤4 | ≤4 | ≤4->8 | 93.7 | 5.8 | |
| Linezolid | 2 | 2 | 0.12-4 | 100.0 | — | |
| Oxacillin resistant (19,721) | Dalbavancin | 0.06 | 0.06 | ≤0.03-0.5 | >99.9 | — |
| Vancomycin | 1 | 1 | 0.25-4 | >99.9 | 0.0 | |
| Erythromycin | >2 | >2 | ≤0.25->2 | 10.9 | 88.8 | |
| Clindamycin | >2 | >2 | ≤0.25->2 | 47.8 | 52.1 | |
| Levofloxacin | >4 | >4 | ≤0.5->4 | 18.3 | 80.1 | |
| Gentamicin | ≤2 | >8 | ≤2->8 | 74.1 | 24.8 | |
| Tetracycline | ≤4 | >8 | ≤4->8 | 81.1 | 18.4 | |
| Linezolid | 1 | 2 | ≤0.25->8 | >99.9 | 0.04 | |
| CoNS | ||||||
| Oxacillin susceptible (2,836) | Dalbavancin | ≤0.03 | 0.06 | ≤0.03-1 | 99.8 | — |
| Vancomycin | 1 | 2 | ≤0.12-4 | 100.0 | 0.0 | |
| Erythromycin | ≤0.25 | >2 | ≤0.25->2 | 66.0 | 33.6 | |
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25->2 | 93.5 | 5.7 | |
| Levofloxacin | ≤0.5 | 4 | ≤0.5->4 | 87.5 | 11.1 | |
| Gentamicin | ≤2 | ≤2 | ≤2->8 | 95.0 | 3.1 | |
| Tetracycline | ≤4 | >8 | ≤4->8 | 86.7 | 12.6 | |
| Linezolid | 1 | 1 | ≤0.25->8 | 99.9 | — | |
| Oxacillin resistant (9,472) | Dalbavancin | ≤0.03 | 0.12 | ≤0.03-2 | 99.2 | — |
| Vancomycin | 1 | 2 | ≤0.12-8 | >99.9 | 0.0 | |
| Erythromycin | >2 | >2 | ≤0.25->2 | 24.1 | 75.4 | |
| Clindamycin | ≤0.25 | >2 | ≤0.25->2 | 57.0 | 41.7 | |
| Levofloxacin | 4 | >4 | ≤0.5->4 | 31.8 | 61.4 | |
| Gentamicin | 4 | >8 | ≤2->8 | 50.7 | 35.3 | |
| Tetracycline | ≤4 | >8 | ≤4->8 | 83.4 | 15.8 | |
| Linezolid | 1 | 1 | ≤0.25->8 | 99.5 | — | |
| E. faecalis | ||||||
| Vancomycin susceptible (10,025) | Dalbavancin | ≤0.03 | 0.06 | ≤0.03-0.5 | >99.9 | — |
| Ampicillin | ≤2 | ≤2 | ≤2->16 | 99.6 | 0.2 | |
| Ciprofloxacin | 1 | >4 | 0.06->4 | 62.2 | 33.6 | |
| Gentamicin (HLc) | ≤500 | >1000 | ≤500->1000 | 68.5 | 31.5 | |
| Linezolid | 1 | 2 | ≤0.25->8 | 99.8 | 0.1 | |
| Vancomycin nonsusceptible (349) | Dalbavancin | >4 | >4 | ≤0.03->4 | 27.8 | — |
| Ampicillin | ≤2 | 4 | ≤2->16 | 96.0 | 4.0 | |
| Ciprofloxacin | >4 | >4 | 0.5->4 | 3.7 | 96.3 | |
| Gentamicin (HL) | >1000 | >1000 | ≤500->1000 | 28.4 | 71.6 | |
| Linezolid | 1 | 2 | 0.25->8 | 98.6 | 1.4 | |
| E. faecium | ||||||
| Vancomycin susceptible (2,578) | Dalbavancin | 0.06 | 0.12 | ≤0.03-2 | 99.6 | — |
| Ampicillin | >16 | >16 | ≤2->16 | 15.6 | 84.4 | |
| Ciprofloxacin | >4 | >4 | 0.06->4 | 8.1 | 83.7 | |
| Gentamicin (HL) | ≤500 | >1000 | ≤500->1000 | 61.8 | 38.2 | |
| Linezolid | 1 | 2 | ≤0.25->8 | 99.6 | 0.3 | |
| Vancomycin nonsusceptible (2,176) | Dalbavancin | >4 | >4 | ≤0.03->4 | 11.4 | — |
| Ampicillin | >16 | >16 | ≤2->16 | 0.8 | 99.2 | |
| Ciprofloxacin | >4 | >4 | ≤0.03->4 | 0.7 | 98.3 | |
| Gentamicin (HL) | ≤500 | >1000 | ≤500->1000 | 64.3 | 35.7 | |
| Linezolid | 1 | 2 | 0.5->8 | 97.6 | 1.8 | |
| βHS (5,316) | Dalbavancin | ≤0.03 | ≤0.03 | ≤0.03-0.25 | 100.0 | — |
| Vancomycin | 0.5 | 0.5 | ≤0.12-1 | 100.0 | — | |
| Penicillin | ≤0.015 | 0.06 | ≤0.015-1 | 99.9 | — | |
| Ceftriaxone | ≤0.25 | ≤0.25 | ≤0.25-4 | 99.9 | — | |
| Erythromycin | ≤0.25 | >2 | ≤0.25->2 | 79.6 | 19.9 | |
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25->2 | 91.4 | 8.2 | |
| Levofloxacin | ≤0.5 | 1 | ≤0.5->4 | 98.6 | 1.3 | |
| Linezolid | 1 | 1 | ≤0.25-2 | 100.0 | — | |
| VGS (2,148) | Dalbavancin | ≤0.03 | ≤0.03 | ≤0.03-0.12 | 100.0 | — |
| Vancomycin | 0.5 | 1 | ≤0.12-2 | >99.9 | — | |
| Penicillin | 0.06 | 1 | ≤0.03->32 | 71.7 | 6.0 | |
| Ceftriaxone | ≤0.25 | 1 | ≤0.25->32 | 92.5 | 4.3 | |
| Erythromycin | ≤0.25 | >2 | ≤0.25->2 | 56.0 | 41.7 | |
| Clindamycin | ≤0.25 | 0.5 | ≤0.25->2 | 89.8 | 9.5 | |
| Levofloxacin | 1 | 2 | ≤0.5->4 | 95.7 | 3.6 | |
| Linezolid | 1 | 1 | ≤0.25-8 | >99.9 | — | |
a
Susceptibility criteria of the CLSI (M100-S18 [3]) were used where available. For dalbavancin, a proposed susceptible breakpoint of ≤0.25 μg/ml for all species was applied for comparisons only with vancomycin.
b
—, no resistant breakpoint criteria have been recommended.
c
HL, high-level resistance.